Aström H
Scand J Respir Dis. 1975;56(6):292-6.
Five patients with mild to moderate asthma were studied after an intravenous saline control followed by atenolol (i.v. 7-9mg) and propranolol (i.v. 0.2-1.0 mg) in a body plethysmograph. Following propranolol, heart rate did not change but specific airway conductance dropped with 65% and airway resistance increased with 130%. Following atenolol, there was a dose-related decrease in heart rate (25% after 9 mg i.v.) and a slight but not significant tendency to a decrease in airway conductance on the highest doses. None of the patients experienced any change in symptoms after administration of atenolol but after propranolol two patients had worsened symptoms. It is concluded that, in contrast to propranolol, atenolol blocks the beta-receptors in the heart preferentially to those in the lungs, and thus could be given to patients with obstructive lung disease.
对5例轻至中度哮喘患者进行了研究,首先进行静脉注射生理盐水对照,然后在体容积描记仪中给予阿替洛尔(静脉注射7 - 9毫克)和普萘洛尔(静脉注射0.2 - 1.0毫克)。给予普萘洛尔后,心率未改变,但比气道传导率下降了65%,气道阻力增加了130%。给予阿替洛尔后,心率呈剂量相关下降(静脉注射9毫克后下降25%),在最高剂量时气道传导率有轻微但不显著的下降趋势。给予阿替洛尔后,所有患者症状均无变化,但给予普萘洛尔后,有2例患者症状加重。结论是,与普萘洛尔不同,阿替洛尔优先阻断心脏中的β受体而非肺部中的β受体,因此可用于阻塞性肺疾病患者。